2. Yancy CW, Januzzi JL Jr., Allen LA, et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018;71:201 30. 3. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/ AHA guideline for the management of heart failure: a report of the American College of Cardiology Foun- dation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147 239. 4. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/ AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70:776 803. 5. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics 2020 update: a report from the American Heart Association. Circulation. 2020;141: e139 596. 6. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/ AHA/HFSA focused update on the new pharmacolog- ical therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016;68:1476 88. 7. Januzzi JL, Butler J, Fombu E, et al. Rationale and methods of the prospective study of biomarkers, symptom improvement, and ventricular remodeling during sacubitril/valsartan therapy for heart failure (PROVE-HF). Am Heart J. 2018;199:130 6. 8. Myhre PL, Vaduganathan M, Claggett B, et al. B- type natriuretic peptide during treatment with sacu- bitril/valsartan: the PARADIGM-HF trial. 